Causes and predictors of immediate and short-term readmissions following percutaneous left atrial appendage closure procedure

J Cardiovasc Electrophysiol. 2022 Oct;33(10):2213-2216. doi: 10.1111/jce.15659. Epub 2022 Sep 1.

Abstract

Introduction: Percutaneous left atrial appendage device closure has been offered as an alternative to anticoagulation for high-risk patients with nonvalvular atrial fibrillation. Given the relative novelty of the procedure, we aimed to analyze the rates and causes of immediate (30 days) and short-term (90 days) readmission after the procedure.

Methods: We performed a retrospective observational study using the Nationwide Readmissions Database for 2018. We studied 29 449 hospitalizations for percutaneous left atrial appendage (LAA) device closure.

Results: In both the 30- and 90-day cohorts, the most common causes of readmissions were gastrointestinal bleeding (16.1% and 14.8%), heart failure exacerbation (11.1% and 11.6%), and atrial fibrillation (6.2% and 7.2%). Female sex, liver disease, chronic kidney disease, chronic pulmonary disease, presence of heart failure, human immunodeficiency virus/acquired immunodeficiency syndrome status, and diabetes mellitus were independently associated with higher odds of readmission in both cohorts.

Conclusion: Our study highlights the need for further deliberation on the choice and duration of anticoagulation periprocedurally after percutaneous LAA closure, especially among those with high bleeding risk. It also highlights the need for optimization of heart failure status periprocedurally to avoid readmissions for exacerbations.

Keywords: anticoagulation; atrial fibrillation; bleeding; left atrial appendage occlusion; readmission.

Publication types

  • Observational Study

MeSH terms

  • Anticoagulants / adverse effects
  • Atrial Appendage* / diagnostic imaging
  • Atrial Appendage* / surgery
  • Atrial Fibrillation* / diagnosis
  • Atrial Fibrillation* / epidemiology
  • Atrial Fibrillation* / surgery
  • Female
  • Heart Failure* / diagnosis
  • Heart Failure* / epidemiology
  • Heart Failure* / therapy
  • Humans
  • Patient Readmission
  • Stroke* / etiology
  • Treatment Outcome

Substances

  • Anticoagulants